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Despite improvement of lymphoma treatments, many patients still
relapse, the majority of whom being elderly and reluctant or unable
to receive iv chemotherapy. It is known that treatment with all-oral
protocols lowered management costs, without impairing efficacy. In
our study, outpatient oral chemotherapy schemes were specifically de-
signed to offer a well tolerated and easy to administer therapeutic op-
tion. This program was planned by clinicians, psycho-oncologists and
hospital pharmacists, the latter providing detailed information on
drugs management. Molecules of widespread use and moderate cost
were employed: NIET (Idarubucin30mg/sqm d1, Procarbazine
100mg/sqm d1-4, Etoposide100mg/sqm d1-4, Dex 20 mg d1-4), FC
(Fludarabine 25 mg/sqm, Cyclophosphamide 150 mg/sqm d1-4), CD
(Cyclophosphamide 100 mg/sqmx2d1-5 Dex 20 mg d1) and Chloram-
bucil 10mg d1-10. A total of 100 patients were evaluated: median age
at treatment start was 77 y (33 – 95), the majority of patients were
unfit (37) or frail (46) according to multiparametric geriatric evaluation.
Fifty-five patients had indolent lymphoma (Chronic Lymphocytic
Leukemia, CLL 29; Small Lymphocytic Lymphoma, SLL 12; others 14),
45 had aggressive lymphoma (Diffuse Large B cell Lymphoma, DBLCL
28, Mantle Cell Lymphoma,MCL 6 and T-cell lymphoma 6, others 5).
Twenty-nine patients had no prior treatment, 49 underwent 1-4 pre-
vious lines of therapy, 11 patients 5-6 lines and 11 patients more than
6 lines. Efficacy and toxicity were evaluated on 62 patients receiving
at least 3 cycles of therapy: 74% had an objective benefit, 14% had
stable disease, 12% had a progressive disease. G3-4 haematological
toxicity was detected in 12 cases and non-haematological G3-4 toxicity
in 2. Psycho-oncological tests revealed that 72% of the patients had a
HADS (Hospital Anxiety and Depression Scale) score below the cut-
off, both at T0 and at T1, suggesting low psychological distress. What
is more, 88% of the patients judged positively the information about
the treatment and the presence of the pharmacist. These data showed
that chemotherapy does not negatively impact the psychological sta-
tus. Our all-oral approach is an efficient alternative to traditional iv
chemotherapy for elderly and frail patients with no cure expectation.
The therapy shows some efficacy, improves the comfort from symp-
toms, is well tolerated and has restrained costs. 
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Data from the German RICOVER-60 study indicate that Vitamin
D deficiency is a risk factor in elderly patients with diffuse large B-
cell lymphomas (DLBCL) treated with Rituximab-containing
chemotherapy (R-CHOP) (Bittenbring et al., J Clin Oncol 2014). A ret-
rospective analysis of cohorts of follicular lymphoma (FL) patients
showed an inferior survival also for FL patients (Kelly et al., J Clin
Oncol 2015). In vitro data suggest that Vitamin D supplementation
could enhance rituximab-mediated cytotoxicity. We measured
prospectively Vitamin D levels in an Italian cohort of 87 newly diag-
nosed patients with B cell lymphomas (62 patients with DLBCL, 25
patients with FL) who were candidates for Rituximab-containing
chemotherapy. Vitamin D levels were considered deficient (<10
ng/ml) in 37 patients (43%), insufficient (10 to 30 ng/ml) in 44 pa-
tients (51%), and normal (>30 to 100 ng/ml) in 6 patients (7%). There
was no difference between FL and DLBCL patients. Looking at pa-
tient characteristics we found a trend for lower Vitamin D levels with
older age (p=0.06). In addition, there was a significant seasonal vari-
ation with highest Vitamin D levels in the third trimester (p=0.006).
As normalization of Vitamin D levels have been shown to improve
in vitro rituximab-mediated cellular cytoxicity by NK cells, we imple-
mented a substitution regimen to achieve Vitamin D levels early dur-
ing treatment. We supplemented Vitamin D (cholecalciferole) in a
daily dose of 25000 U for a period that varied according to the initial
Vitamin D levels and subsequently continued maintenance with
cholecalciferole 25000 U once a week. A second determination of Vi-
tamin D levels after a median of 1.1 month in 24 patients showed a
significant increase of Vitamin D levels from 14+1.4 ng/ml to 27+1.9
(mean+SEM, p=0.001). Supplementation resulted in rapid normaliza-
tion of Vitamin D levels in 10/24 patients (42%) No episodes of hy-
pervitaminosis or hypercalcemia were observed. In 13 patients
without supplementation, Vitamin D levels showed no significant
variation (15+3 ng/ml at diagnosis vs 12+1.6 ng/ml during therapy).
Studies of Vitamin D levels on NK cell population are ongoing. We
conclude that Vitamin D deficiency is frequent in patients with ag-
gressive and indolent B cell lymphomas also in Central Italy. Vitamin
D levels can be rapidly normalized using a daily substitution regimen.
This may help to improve efficiency of rituximab-containing treat-
ment regimens. 
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Overexpression of MYC and BCL2 and low expression of BCL6 as-
sessed by HIC have been reported as negative prognostic factors in
DLBCL. We recently presented (Botto B, ASH 2014) a pilot study, that
suggested a prognostic score based on overexpression of MYC, BCL2
and low expression of BLC6, assessed by HIC, in a retrospective co-
hort of 69 de novo DLBCL, with an high proliferation index (MIB1
>70%), treated with R-CHOP between 2010 and 2013. The aim of
the present study was to expand the analysis and validate this prog-
nostic score in a larger retrospective cohort of DLBCL, without re-
strictions of MIB1. de novo DLBCL patients, treated with R-CHOP
between 2003 and 2013 were included. Cases enrolled in the previous
pilot study were considered as control group. Samples were investi-
gated using TMA sections for MYC, while BCL2 and BCL6 staining
had been evaluated at diagnosis. Positivity was defined for MYC and
BCL2/BCL6 expression by immunostain if >40%, >40% and 25% of
cells showed positive expression, respectively. FISH is ongoing.
Among 119 patients eligible, 99 were evaluable, 20 were not due to
missing clinical data. Clinical characteristics were: median age 63.5
years (IQR 52;73), 66 (68%) stage III-IV, 27 (28%) with LDH upper
normal and 30 (30%) with IPI >2. These characteristics are superim-
posable to those of the pilot study, a part for a lower rate of IPI>2
(30% vs 67%). Median MIB1 at diagnosis was 70% (IQR 60-85). At
the moment of the present analysis, MYC was investigated in 45/99
cases and an overespression was detected in 10 (22%). BCL2 and
BCL6 were analyzed in 77 and 74 cases, with BCL2 overexpression
in 64 (83%) and BCL6 low expression in 25 (34%). Median 2y-PFS
and OS were 71% and 84% respectively. Applying the prognostic
score defined in the previous pilot study (risk of 2 points for MYC or
BCL2 positivity and 1 point for BCL6 negativity, pooled scores 0-1, 2
and >3) 2y-PFS were different across the 3 groups: 100% vs 83% vs
64% (p 0.002). While in the pilot study no differences in OS were
showed, in this expanded cohort OS were different across the groups:
100% vs 89% vs 82% (p 0.07). Our data showed that the HIC prog-
nostic score based on MYC, BCL2 and BCL6 expression, outlined in
the previous study, was applicable, reproducible and valid in a larger
cohort of DLBCL, regardless of MIB1, forecasting significant different
PFS and OS rates. This study provides to extend HIC and FISH analy-
sis in a total sample of above 200 cases.
haematologica | 2015; 100(s3) | 95
2015_SIE_ok.qxp_Layout 1  22/09/15  12:36  Pagina 95
